Kumar P., & Aggarwal R. (2016). An overview of triple-negative breast cancer. Archives of gynecology and obstetrics, 293, 247–269.https://doi.org/10.1007/ws00404-015-3859-y

Kumar V, Abbas AK, Aster JC (2017) Robbins and cotran pathologic basis of disease, 10th edn. Elsevier

Zagami P, Carey LA (2022) Triple negative breast cancer: pitfalls and progress. NPJ breast cancer 8(1):95. https://doi.org/10.1038/s41523-022-00468-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Costa RLB, Gradishar WJ (2017) Triple-negative breast cancer: current practice and future directions. J Oncol Prac 13(5):301–303. https://doi.org/10.1200/JOP.2017.023333

Article  Google Scholar 

Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, Zhou Q (2019) Prognostic value of Ki-67 in patients with resected triple-negative breast cancer: a meta-analysis. Front Oncol 9:1068. https://doi.org/10.3389/fonc.2019.01068

Article  PubMed  PubMed Central  Google Scholar 

Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121(7):2750–2767. https://doi.org/10.1172/JCI45014

Article  CAS  PubMed  PubMed Central  Google Scholar 

McNamara KM, Yoda T, Takagi K, Miki Y, Suzuki T, Sasano H (2013) Androgen receptor in triple negative breast cancer. J Steroid Biochem Mole Bio 133:66–76. https://doi.org/10.1016/j.jsbmb.2012.08.007

Article  CAS  Google Scholar 

Rampurwala M, Wisinski KB, O’Regan R (2016) Role of the androgen receptor in triple-negative breast cancer. Clin Ad Hematol & Oncol: H&O 14(3):186. https://pmc.ncbi.nlm.nih.gov/articles/PMC5221599/. Accessed 19 Oct 2024

Gucalp A, Traina TA (2016) Targeting the androgen receptor in triple-negative breast cancer. Curr Probl Cancer 40(2–4):141–150. https://doi.org/10.1016/j.currproblcancer.2016.09.004

Article  PubMed  PubMed Central  Google Scholar 

Luo X, Shi YX, Li ZM, Jiang WQ (2010) Expression and clinical significance of androgen receptor in triple negative breast cancer. Chin J Cancer 29(6):585–590. https://doi.org/10.5732/cjc.009.10673

Article  CAS  PubMed  Google Scholar 

Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R (2010) Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol An Off J United States and Canadian Acad Pathol Inc 23(2):205–212. https://doi.org/10.1038/modpathol.2009.159

Article  CAS  Google Scholar 

He J, Peng R, Yuan Z, Wang S, Peng J, Lin G, Jiang X, Qin T (2012) Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Medical oncology (Northwood, London, England) 29(2):406–410. https://doi.org/10.1007/s12032-011-9832-0

Article  CAS  PubMed  Google Scholar 

Park S, Koo J, Park HS, Kim JH, Choi SY, Lee JH, Park BW, Lee KS (2010) Expression of androgen receptors in primary breast cancer. Ann Oncol : Official J Euro Soc Med Oncol 21(3):488–492. https://doi.org/10.1093/annonc/mdp510

Article  CAS  Google Scholar 

Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L, De Laurentiis M, Puglisi F, Arpino G (2018) Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev 68:102–110. https://doi.org/10.1016/j.ctrv.2018.06.005

Article  CAS  PubMed  Google Scholar 

Pan Y, Yuan Y, Liu G, Wei Y (2017) P53 and Ki-67 as prognostic markers in triple-negative breast cancer patients. PloS one 12(2):e0172324. https://doi.org/10.1371/journal.pone.0172324

Article  CAS  PubMed  PubMed Central  Google Scholar 

Govindan S, Siraganahalli Eswaraiah M, Basavaraj C, Adinarayan M, Sankaran S, Bakre M (2020) Androgen receptor mRNA levels determine the prognosis in triple-negative breast cancer patients. BMC cancer, 20(1).https://doi.org/10.1186/s12885-020-07218-0

Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, O’Shaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J (2018) Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer. J clin oncol : Official J Am Soc Clin Oncol 36(9):884–890. https://doi.org/10.1200/JCO.2016.71.3495

Article  CAS  Google Scholar 

Jiang H, Ouyang Q, Yin Y, Tong Z, Shen K, Yuan Z, Geng C, Liu Y, Song G, Ran R, Li W, Qu Q, Wang M, Meng L, Tong Y, Li H (2022) Proxalutamide in patients with AR-positive metastatic breast cancer: results from an open-label multicentre phase Ib study and biomarker analysis. Euro J Cancer (Oxford, England : 1990) 176:1–12. https://doi.org/10.1016/j.ejca.2022.08.025

Article  CAS  Google Scholar 

Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, Blackwell K, Rugo H, Nabell L, Forero A, Stearns V, Doane AS, Danso M, Moynahan ME, Momen LF, Gonzalez JM, Akhtar A, Giri DD, Patil S, Feigin KN, Translational Breast Cancer Research Consortium (TBCRC 011) (2013) Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res: An Off J Am Assoc Cancer Res 19(19):5505–5512. https://doi.org/10.1158/1078-0432.CCR-12-3327

Article  CAS  Google Scholar 

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE (2016) Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the high-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol 70(6):963–970. https://doi.org/10.1016/j.eururo.2016.04.023

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonnefoi H, Lerebours F, Pulido M, Arnedos M, Tredan O, Dalenc F, Guiu S, Teixeira L, Mollon D, Levy C, Verret B, Dawood H, Deiana L, Mouret Reynier MA, Augereau P, Canon JL, Huchet N, Guyonneau C, Lemonnier J, MacGrogan G, Iggo R (2025) Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3–06 START): a multicentre, non-comparative, randomised, phase 2 trial. The Lancet. Oncology, S1470–2045(24)00737-X. Advance online publication. https://doi.org/10.1016/S1470-2045(24)00737-X

Vaid PM, Puntambekar A, Kanse P, Kadu S, Agrawal P, Khatpe A et al (2024) Molecular profiling of a triple-negative breast cancer cohort in India for EGFR and AR expression analyzed for patient outcomes showed a distinct subset of cellular co-expression. medRxiv 2024–10.https://doi.org/10.1101/2024.10.25.24316141

Kale AS, Shantappa R, Raju GS, Jena S (2022) A study of androgen receptor expression in triple negative breast cancer. J Cardiovasc Dis Res 13(7):940–52. https://jcdronline.org/admin/Uploads/Files/63625bbd152de2.29087813.pdf

Ricciardi GRR, Adamo B, Ieni A, Licata L, Cardia R, Ferraro G et al (2015) Androgen receptor (AR), E-cadherin, and Ki-67 as emerging targets and novel prognostic markers in triple-negative breast cancer (TNBC) patients. PloS one 10(6):e0128368. https://doi.org/10.1371/journal.pone.0128368

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patnayak R, Jena A, Bhargavi D, Chowhan AK (2018) Androgen receptor expression in triple negative breast cancer-study from a tertiary health care center in South India. Indian J Med Paedia Oncol 39(01):28–31. https://doi.org/10.4103/ijmpo.ijmpo_4_17

Article  Google Scholar 

Choi JE, Kang SH, Lee SJ, Bae YK (2015) Androgen receptor expression predicts decreased survival in early stage triple-negative breast cancer. Ann Surg Oncol 22:82–89. https://doi.org/10.1245/s10434-014-3984-z

Article  PubMed  Google Scholar 

Anand A, Singh KR, Kumar S, Husain N, Kushwaha JK, Sonkar AA (2017) Androgen receptor expression in an Indian breast cancer cohort with relation to molecular subtypes and response to neoadjuvant chemotherapy-a prospective clinical study. Breast Care 12(3):160–164. https://doi.org/10.1159/000458433

Article  PubMed  PubMed Central  Google Scholar 

Srivastava TP, Ajmeriya S, Goel I, Talukdar J, Srivastava A, Parshad R, Karmakar S (2024) Prognostic role of androgen receptor splice variant 7 (AR-V7) in the pathogenesis of breast cancer. BMC cancer 24(1):1398. https://doi.org/10.1186/s12885-024-13165-x

Article  CAS  PubMed  PubMed Central  Google Scholar 

Asano Y, Kashiwagi S, Goto W, Tanaka S, Morisaki T, Takashima T et al (2017) Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancers 9(1):4. https://doi.org/10.3390/cancers9010004

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M et al (2014) Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers 6(3):1351–1362. https://doi.org/10.3390/cancers6031351

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res : BCR 22(1):61. https://doi.org/10.1186/s13058-020-01296-5

Article  PubMed  PubMed Central  Google Scholar 

Wang C, Pan B, Zhu H, Zhou Y, Mao F, Lin Y, Xu Q, Sun Q (2016) Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget 7(29):46482–46491. https://doi.org/10.18632/oncotarget.10208

Article